Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer
about
Inhibiting heat shock factor 1 in human cancer cells with a potent RNA aptamerTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerTargeting Cell Survival Proteins for Cancer Cell DeathAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersHeat shock and other apoptosis-related proteins as therapeutic targets in prostate cancerMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionAcetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.Cytoplasmic HSP90α expression is associated with perineural invasion in pancreatic cancer.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsNovel drugs targeting the androgen receptor pathway in prostate cancer.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsMacrocyclic inhibitors of hsp90Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90Androgen receptor signaling in prostate cancer.Targeting heat shock proteins in metastatic castration-resistant prostate cancer.Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer CellsProgress in the mechanism and drug development of castration-resistant prostate cancer.Drug discovery in advanced prostate cancer: translating biology into therapy.Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.Heat shock protein 90 (hsp90) expression and breast cancer.First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.Hyperglycaemic conditions perturb mouse oocyte in vitro developmental competence via beta-O-linked glycosylation of heat shock protein 90.A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
P2860
Q21132046-E7791635-8159-4515-B875-7D0BC51AE6BCQ26750620-2BA0E60C-3D71-4E0C-8041-1E4E2040E484Q26765447-4CC49824-9138-4D84-8860-0F80BD30A5D6Q27022514-46F3C07D-90F8-4915-8AEC-423B2B05DB88Q27026128-26196CB2-89AE-4D05-92F1-79E79B42B9AFQ28829301-A2519AEE-D967-4841-B0CF-E2B0074F490DQ30353562-E731C6E2-EB23-48B9-BE03-04B8CE045234Q33898794-108C1B34-70A3-44DF-AC3A-88C699A39A69Q34164027-35970AE5-E260-4638-A85C-18D2D8F45D3EQ34395777-E77CAB64-C9A1-4AAB-846B-CA8293E69751Q34677194-0F9DB794-F605-41FE-B382-4482F6D59A77Q35017513-ADAB1ADF-2CC6-4B43-8C84-F01FD0D8B204Q35057071-68B72491-97F0-414F-8C2A-6B0338BB782CQ35849973-06328865-984C-43FD-8B0A-8A29EB38FCF0Q36635865-321A9847-D640-446D-AD99-52DD6B998958Q36642876-8C8ACF2E-9352-493C-8506-139CBDE5515DQ37204596-00320CE6-1507-4EDB-AEF7-EE9295DCCAF5Q37274132-2C7C09BC-04B3-4887-AD54-6366E47CB24AQ37293806-0B8EE36B-437F-43CC-A1AE-496A284D332FQ38175320-B0307C16-53E2-4A8E-A8DB-B34B29D33188Q38289945-0CC02672-8312-4F40-81AF-A86064D34F98Q38759678-1101BF75-B9F1-47C3-BB10-22494FBD8DA6Q38826609-5832D82E-863F-4D55-B82B-F5A9789682E7Q38839110-8B7A65AA-5545-480D-8A0D-5FB60A6CF5F9Q38909847-EDA9F3A9-9421-4ADF-8309-A2AB90B9E0A7Q39329793-39AFA858-009F-4378-8FC3-A5991BA494E0Q42362272-9401D9F5-FAC0-4D29-82BE-AE5CBD8E6B69Q42922811-E1E76189-8727-4723-B080-55B44E4F5447Q48238685-D9F2C2B0-DB75-45B9-837B-9520733B537DQ48604613-F3A66ED6-A6D5-4C83-8D75-B6D598C08F76Q53808764-DD5F0058-82C9-4E2D-8E78-A742885AB5B6
P2860
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Multicenter phase II trial of ...... tion-resistant prostate cancer
@ast
Multicenter phase II trial of ...... tion-resistant prostate cancer
@en
type
label
Multicenter phase II trial of ...... tion-resistant prostate cancer
@ast
Multicenter phase II trial of ...... tion-resistant prostate cancer
@en
prefLabel
Multicenter phase II trial of ...... tion-resistant prostate cancer
@ast
Multicenter phase II trial of ...... tion-resistant prostate cancer
@en
P2093
P2860
P921
P1433
P1476
Multicenter phase II trial of ...... tion-resistant prostate cancer
@en
P2093
Franklin Chu
Glenn Bubley
Joi Dunbar
Matthew D Galsky
Robert W Ross
Sandy Srinivas
Walter M Stadler
William K Oh
P2860
P304
P356
10.1016/J.UROLOGY.2011.04.041
P407
P577
2011-07-18T00:00:00Z